Please login to the form below

Not currently logged in
Email:
Password:

Senior appointments at NextPharma Technologies

Andrew Kelley, Pierre Delavaud and Matthew Wilder join the contract manufacturing organisation

Contract manufacturing organisation (CMO) NextPharma Technologies has added Andrew Kelley, Pierre Delavaud and Matthew Wilder to its senior team.

Kelley has been appointed chief operating officer of the Surrey, UK-based firm; Delavaud (pictured) will take over as executive VP sales and marketing; and Matthew Wilder joins as VP of US sales and marketing.

The most experienced new employee is Kelley. He has spent more than 27 years in the pharma industry and was recently VP of business development Europe and Asia-Pacific at Canada-based CMO Patheon.

Previous positions have included VP of European operations at Catalent and manufacturing manager at Boehringer Ingelheim.

Andrew Kelley - NextPharmaPierre Delavaud - NextPharmaMatthew Wilder - NextPharma
Andrew Kelley, Pierre Delavaud and Matthew Wilder

Delavaud joins NextPharma from SkyePharma where he had served as executive VP of sales and business development since September, 2011.

Prior to that he spent 14 years at Catalent serving in several senior positions, including VP of business development, global pharmaceutical softgel.

Wilder was most recently at Sanofi, where he had been for ten years, holding roles that included divisional sales manager and regional sales director.

Franck Latrille, NextPharma's CEO, said: “We are delighted to welcome our three new colleagues to our growing team at NextPharma. This is an exciting time for the company, and we are confident that with the injection of their expertise to the team, we can continue to improve our business offerings.”

4th September 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...